Clinical and spectroscopic improvement in HIV-associated cognitive impairment
Clinical and spectroscopic improvement in HIV-associated cognitive impairment
复制标题
DOI：
10.1212/wnl.56.1.112
复制
发表时间：
2001-01-09
期刊：
影响因子：
9.9
通讯作者：
Lubetzki, C
中科院分区：
文献类型：
--
作者：
Stankoff, B;Tourbah, A;Lubetzki, C
为了评估高效抗逆转录病毒治疗（HAART）对艾滋病相关认知障碍的影响，对22例有（n = 11）和无（n = 11）认知障碍的艾滋病患者进行临床和MRS评估，每3个月一次，持续9个月。19名患者在研究开始时接受HAART治疗，21名患者在2个月后接受HAART治疗。认知障碍患者表现为额皮质下缺陷和额叶白质n -乙酰-天冬氨酸减少。这些临床和代谢异常在HAART治疗中部分逆转，而在认知功能未受损的患者中则保持在正常范围内。
To assess the impact of highly active antiretroviral therapy (HAART) on AIDS-associated cognitive impairment, 22 patients with AIDS with (n = 11) and without (n = 11) cognitive deficit were evaluated clinically and by MRS every 3 months for 9 months. Nineteen patients were on HAART at study entry, 21 after 2 months. Cognitively impaired patients presented with a subcorticofrontal deficit and decreased N-acetyl-aspartate in frontal white matter. These clinical and metabolic abnormalities reversed partially on HAART, whereas they remained within normal limits in cognitively unimpaired patients.